Beryl Drugs Limited will convene a board meeting on June 16, 2026, to approve the shifting of its registered office within the local limits of Indore. The meeting is scheduled to take place at 02.00 P.M. at the company's current registered office.

The Board of Directors will consider the proposal to change the address from 133, Kanchan Bagh, Indore-452001 to 29, Neer Nagar, Mayank Water Park Road, Bicholi, Indore-452016. This move is subject to the approval of the board.

The intimation regarding the 3/2026-2027 board meeting was submitted to the Bombay Stock Exchange Limited. The notice was signed by Sanjay Sethi, Managing Director of beryl drugs .

Meeting Details

Proposed Address Change

Beryl Drugs Limited reported a net profit of ₹42.48 lakh for the financial year ended March 31, 2026, a decrease from ₹56.75 lakh in the previous year. Revenue from operations for the year stood at ₹1931.02 lakh, compared to ₹2255.48 lakh in FY25. The decline in revenue was attributed to a temporary suspension of production operations in the Blow Fill Seal (BFS) Section following an order from the Office of the Controller, Food and Drugs Administration, Madhya Pradesh, which was later revoked in November 2025.

The board of directors, chaired by Sudhir Sethi, approved the audited financial results for the quarter and year ended March 31, 2026. The Statutory Auditor, M/s Subhash Chand Jain Anurag & Associates Chartered Accountants, issued an unmodified opinion on the results. The auditor highlighted an unrecorded potential liability regarding professional tax and the adoption of Ind AS 116 – Leases, which resulted in the recognition of a Right-of-Use asset of ₹27.75 lakh and a Lease Liability of ₹4.95 lakh.

Financial Performance

The company's total expenses for FY26 amounted to ₹1931.02 lakh, lower than the ₹2255.48 lakh recorded in the previous year. Profit before tax for the year was ₹58.80 lakh, compared to ₹85.43 lakh in FY25. For the quarter ended March 31, 2026, the company reported a net profit of ₹56.25 lakh and revenue from operations of ₹546.74 lakh.

Key Financial Metrics (FY26)

The company's cash and cash equivalents as of March 31, 2026, were ₹27.35 lakh, down from ₹81.44 lakh in the previous year. The balance sheet total assets stood at ₹1496.33 lakh as of March 31, 2026. The filing was submitted to the Bombay Stock Exchange Limited in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.